Robert Charles Jahr - 14 Aug 2026 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: OTLK
Reported as of: 14 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2026, 20:57:45 UTC
Prior SEC filing: 23 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Lawrence Kenyon, Attorney-in-Fact

Key filing fact

Robert Charles Jahr filed Form 4 for Outlook Therapeutics, Inc. (OTLK) on 14 Aug 2026.

Key facts

This page summarizes Robert Charles Jahr's Form 4 filing for Outlook Therapeutics, Inc. (OTLK).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Aug 2026, 20:57.

Change

Previous filing in this sequence was filed on 23 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002076177 Primary reporting owner

Jahr Robert Charles

Relationship: Chief Executive Officer, Director
Address: C/O OUTLOOK THERAPEUTICS, INC., 111 S. WOOD AVE, UNIT #100, ISELIN
Signature: /s/ Lawrence Kenyon, Attorney-in-Fact
Signature date: 14 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OTLK transaction

Common Stock

Purchase

Transaction value
Shares: +151,515
Change %
Price
Shares after: 151,515
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OTLK transaction Derivative

Warrants (right to buy)

Purchase

Transaction value
Shares: +151,515
Change %
Price
Shares after: 151,515
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 151,515
Exercise price: $1.10
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.

Footnote F2

The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031.